30 closest matches · ranked by relevance
Locally Advanced Basal Cell Carcinoma · Skin Cancer · Cutaneous Malignancy
Primary: Percentage of Patients With Local-regional Control Rate — 100 percentage
Head and Neck Cancer · Head and Neck Neoplasms
Primary: Number of Participants Who Experience a Pathologic Complete Response (pCR) — 0; 0 Participants
Carcinoma, Basal Cell
Primary: The Number of Patients With a Score of 21 or Greater by the Visual Assessment Weighted Score (VAWS). — 34 Participants
HPV-Related Squamous Cell Carcinoma · HNSCC
Primary: Evaluate the Tumor Shrinkage (%) to Measure the Deep Response Rate (DRR) — 25; 26; 0 Participants
Head and Neck Carcinoma
Primary: Overall Response Rate — 22.7 percentage
Squamous Cell Carcinoma of the Head and Neck · Nasopharyngeal Carcinoma · Salivary Gland Cancer
Primary: Local Control Rate — 1; 5 Participants
Head and Neck Cancer
Primary: Clinical Response Rate Following Induction Chemotherapy — 10; 20; 9 Participants
Carcinoma, Squamous Cell of Head and Neck · HPV Positive Oropharyngeal Squamous Cell Carcinoma · Hypopharyngeal Cancer
Primary: Maximum Tolerated Dose of Cisplatin — 30 mg/m2
Carcinoma, Basal Cell
Primary: Change in Occurence of Local Skin Reaction (LSR) Side Effects TOTAL COMPOSITE SCORE — 7; 9; 4; 2 score on a scale
Squamous Cell Carcinoma of the Head and Neck
Primary: Number of Subjects With Dose Limiting Toxicities — 0 Participants
Oropharynx Squamous Cell Carcinoma
Primary: Progression-free Survival (PFS) — 65 percentage of patients
Head and Neck Cancer
Primary: 1-year Local Control — NA; NA months
Head and Neck Cancer · Cancer of the Pharynx · Cancer of the Larynx
Primary: Llocoregional Recurrence — 27 Participants
Cancer of Head and Neck · Head and Neck Cancer · Neoplasms, Head and Neck
Primary: Locoregional Recurrence Rates in Cohorts 1 and 2 — 2; 2 Participants
Head and Neck Cancer
Primary: Overall Response Rate — 0 patients
HPV-Related Squamous Cell Carcinoma · Head and Neck Squamous Cell Carcinoma
Primary: Progression-free Survival (PFS) at 2 Years — 75.5 percentage of patients
Name Human Papillomavirus Positive Oropharyngeal Squamous Cell Carcinoma · Stage II Oropharyngeal Squamous Cell Carcinoma · Stage III Hypopharyngeal Squamous Cell Carcinoma
Primary: Pathologic Complete Response Rate — 45.5 percentage of complete response
Basal Cell Carcinoma of the Skin · Recurrent Skin Cancer
Primary: Percent Change in Biomarker (GLI2 Protein) Levels — 75 percentage decrease
Basal Cell Carcinoma · Skin Cancer · Cancer of the Skin, Basal Cell
Primary: Part 1: Percentage of Subjects With Discontinuations Due to Adverse Events — 0 Participants
Head and Neck Squamous Cell Carcinoma
Primary: Major Pathologic Response — 22 Participants
Squamous Cell Carcinoma of the Head and Neck
Primary: Percentage of Participants With Pathologic Complete Response (pCR) as Determined by Local Pathologic Review — 16.7; 50.0 percentage of participants
Oral Squamous Cell Carcinoma
Primary: Pathologic Response. — 25; 2; 4; 4 Participants
Squamous Cell Cancers of the Head and Neck
Primary: Tumor Shrinkage — 2; 9; 36 Participants
Adenoid Cystic Carcinoma
Primary: Objective Response Rate (ORR) — 0 percentage of participants
Basal Cell Carcinoma
Primary: This is a Study to Measure the Efficacy of the Nd:YAG Laser to Cause Complete Regression of Basal Cell Carcinoma. — 28 tumors
Squamous Cell Carcinoma of the Head and Neck
Primary: Clinical Complete Response Rate at the Primary Tumor — 16 participants
Squamous Cell Carcinoma of the Head and Neck
Primary: Objective Response Rate (ORR) — 0; 2 participants
Squamous Cell Carcinoma of Head and Neck
Primary: Objective Response Rate (ORR) — 48.5 Percentage of Participants
Head and Neck Cancer · Squamous Cell Carcinoma
Primary: Change in Tumor Size — 1; 3; 11 Participants
Squamous Cell Carcinoma of the Head and Neck
Primary: Number of Participants With Overall Response — 7; 5 Participants